EP2254867A1 - Dérivés de sulfonamide substitués - Google Patents

Dérivés de sulfonamide substitués

Info

Publication number
EP2254867A1
EP2254867A1 EP09717566A EP09717566A EP2254867A1 EP 2254867 A1 EP2254867 A1 EP 2254867A1 EP 09717566 A EP09717566 A EP 09717566A EP 09717566 A EP09717566 A EP 09717566A EP 2254867 A1 EP2254867 A1 EP 2254867A1
Authority
EP
European Patent Office
Prior art keywords
piperidin
methyl
methoxy
aryl
methylpiperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09717566A
Other languages
German (de)
English (en)
Inventor
Stefan OBERBÖRSCH
Ruth Jostock
Klaus Schiene
Jean De Vry
Tieno Germann
Sabine Hees
Stefan Schunk
Melanie Reich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to EP09717566A priority Critical patent/EP2254867A1/fr
Publication of EP2254867A1 publication Critical patent/EP2254867A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the present invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicaments containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.
  • bradykinin 1 receptor B1 R
  • B2R bradykinin 2 receptor
  • B1 R bradykinin 1 receptor
  • a rapid and pronounced induction of B1 R takes place on neuronal cells, but also various peripheral cells, such as fibroblasts, endothelial cells, granulocytes, macrophages and lymphocytes.
  • a switch from a B2R to a B1 R dominance thus occurs on the cells involved.
  • cytokines interleukin-1 (IL-1) and tumour necrosis factor alpha (TNF ⁇ ) are involved to a considerable degree in this upwards regulation of B1 R (Passos et al. J. Immunol. 2004, 172, 1839-1847).
  • B1 R-expressing cells After activation with specific ligands, B1 R-expressing cells then themselves can secrete inflammation-promoting cytokines such as IL-6 and IL-8 (Hayashi et al., Eur. Respir. J. 2000, 16, 452-458). This leads to inwards migration of further inflammation cells, e.g. neutrophilic granulocytes (Pesquero et al., PNAS 2000, 97, 8140-8145).
  • the bradykinin B1 R system can contribute towards chronification of diseases via these mechanisms. This is demonstrated by a large number of animal studies (overviews in Leeb-Lundberg et al., Pharmacol. Rev. 2005, 57, 27-77 und Pesquero et al., Biol. Chem. 2006, 387, 119-126). On humans too, an enhanced expression of B1R, e.g. on enterocytes and macrophages, in the affected tissue of patients with inflammatory intestinal diseases (Stadnicki et al., Am. J. Physiol. Gastrointest. Liver Physiol.
  • B1 R antagonists On the basis of the pathophysiological relationships described, there is a great therapeutic potential for the use of B1 R antagonists on acute and, in particular, chronically inflammatory diseases. These include diseases of the respiratory tract (bronchial asthma, allergies, COPD/chronic obstructive pulmonary disease, cystic fibrosis etc.), inflammatory intestinal diseases (ulcerative colitis, CD/Crohn's disease etc.), neurological diseases (multiple sclerosis, neurodegeneration etc.), inflammations of the skin (atopic dermatitis, psoriasis, bacterial infections etc.) and mucous membranes (Behcet's disease, pelvitis, prostatitis etc.), rheumatic diseases (rheumatoid arthritis, osteoarthritis etc.), septic shock and reperfusion syndrome (following cardiac infarction, stroke).
  • diseases of the respiratory tract bronchial asthma, allergies, COPD/chronic obstructive pulmonary disease, cystic fibrosis etc.
  • the bradykinin (receptor) system is moreover also involved in regulation of angiogenesis (potential as an angiogenesis inhibitor in cancer cases and macular degeneration on the eye), and B1 R knockout mice are protected from induction of obesity by a particularly fat-rich diet (Pesquero et al., Biol. Chem. 2006, 387, 119-126). B1 R antagonists are therefore also suitable for treatment of obesity.
  • B1 R antagonists are suitable in particular for treatment of pain, in particular inflammation pain and neuropathic pain (Calixto et al., Br. J. Pharmacol. 2004, 1- 16), and here in particular diabetic neuropathy (Gabra et al., Biol. Chem. 2006, 387, 127-143). They are furthermore suitable for treatment of migraine.
  • One object of the present invention was therefore to provide novel compounds which are suitable in particular as pharmacological active compounds in medicaments, preferably medicaments for treatment of disorders or diseases which are at least partly mediated by B1 R receptors.
  • the invention provides substituted sulfonamide derivatives of the general formula I
  • Q represents a single bond, -O- or -CH 2 -;
  • R 1 represents aryl or heteroaryl or denotes an aryl or heteroaryl bonded via a Ci- 3 -alkylene group
  • R 2 and R 3 are defined as described under (i) or (ii):
  • R 2 represents H, Ci -6 -alkyl, C 3-8 CyClOaIKyI, aryl or heteroaryl; or denotes a C 3- 8-cycloalkyl, aryl or heteroaryl bonded via a Ci -6 -alkylene group, C 2-6 - alkenylene group or C 2 -6-alkynylene group;
  • R 3 represents H, Ci -6 -alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci- 6 -alkylene group, C 2 - 6 -alkenylene group or C 2 - 6-alkynylene group;
  • R 2 and R 3 together form a heterocyclic ring, which can be fused with an aryl or heteroaryl radical,
  • R 8 represents a radical chosen from the group consisting of H, Ci- 6 -alkyl, C 3-8 - cycloalkyl, aryl, heteroaryl or an aryl, heteroaryl or C 3-8 -cycloalkyl bonded via a
  • R 17 represents a radical chosen from the group consisting of H, Ci- 6 -alkyl, C 3-8 - cycloalkyl, aryl, heteroaryl or an aryl, heteroaryl or C 3-8 -cycloalkyl bonded via a
  • Ci- 3 -alkylene group Ci- 3 -alkylene group
  • R 6 represents H, C 1-6 -alkyl, or a C 3 - 8 -cycloalkyl bonded via a d -3 -alkylene group, an aryl bonded via a Ci -3 -alkylene group or a heteroaryl bonded via a Ci -3 - alkylene group,
  • d represents 0 or 1 and R 14 and R 15 together represent a fused-on unsubstituted or substituted aryl or heteroaryl radical;
  • Ci -6 -alkyl, Ci- 6 -alkylene, C 2-6 -alkenylene, C 2- 6-alkynylene, C 3 - 8 -cycloalkyl, heterocycloalkyl, aryl and heteroaryl can in each case be unsubstituted or substituted once or several times by identical or different radicals and the abovementioned radicals Ci- 6 -alkyl, Ci -6 -alkylene, C 2-6 - alkenylene and C 2-6 -alkynylene can in each case be branched or unbranched;
  • n 0 or 1.
  • halogen preferably represents the radicals F, Cl, Br and I, particularly preferably the radicals F, Cl and Br.
  • Ci -6 -alkyl includes acyclic saturated hydrocarbon radicals having 1 , 2, 3, 4, 5 or 6 C atoms, which can be branched- or straight-chain (unbranched) and unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different radicals.
  • the alkyl radicals can preferably be chosen from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso- pentyl, neo-pentyl and hexyl.
  • alkyl radicals can be chosen from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl and tert-butyl.
  • C 2 - 6 -alkenyl includes acyclic unsaturated hydrocarbon radicals having 2, 3, 4, 5 or 6 C atoms, which can be branched or straight-chain (unbranched) and unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different radicals.
  • Alkenyl radicals can preferably be chosen from the group consisting of vinyl, prop-1-enyl, allyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, but-1 ,3- dienyl, 2-methylprop-1-enyl, but-2-en-2-yl, but-1-en-2-yl, pentenyl and hexenyl.
  • alkenyl radicals can be chosen from the group consisting of vinyl, prop-1-enyl, allyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, but-1 ,3-dienyl, 2-methylprop-1-enyl, but-2-en-2-yl and but-1-en-2-yl.
  • Ca- ⁇ -cycloalkyl denotes cyclic saturated hydrocarbon radicals having 3, 4, 5, 6, 7 or 8 carbon atoms, which can be unsubstituted or substituted once or several times, for example by 2, 3, 4 or 5 identical or different radicals, on one or more ring members.
  • C 3 - 8 -Cycloalkyl can preferably be chosen from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • heterocycloalkyl designates saturated heterocyclic rings which can contain as ring members, chosen independently of one another, 1 , 2, 3, 4 or 5 identical or different hetero atoms, preferably from the group N, O or S.
  • bonding to the heterocycloalkyl is preferably via one of the carbon ring members of the heterocycloalkyl.
  • 3- to 8-membered heterocycloalkyls can be, in particular, 4-, 5- or 6-membered.
  • 3- to 8-membered heterocycloalkyls are azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, dioxanyl and dioxolanyl, which can optionally be substituted as explained below.
  • aryl denotes aromatic hydrocarbons, in particular phenyls and naphthyls.
  • the aryl radicals can also be condensed with further saturated, (partially) unsaturated or aromatic ring systems.
  • Each aryl radical can be unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, wherein the substituents on the aryl can be identical or different and can be in any desired and possible position of the aryl.
  • Aryl can advantageously be chosen from the group consisting of phenyl, 1- naphthyl and 2-naphthyl, which can in each case be unsubstituted or substituted once or several times, for example by 2, 3, 4 or 5 radicals.
  • heteroaryl represents a 5-, 6- or 7-membered cyclic aromatic radical which contains at least 1 , if appropriate also 2, 3, 4 or 5 hetero atoms, wherein the hetero atoms can be identical or different and the heteroaryl can be unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different radicals.
  • the substituents can be bonded in any desired and possible position of the heteroaryl.
  • the heterocyclic ring can also be part of a bi- or polycyclic, in particular a mono-, bi- or tricyclic system, which can then be more than 7- membered in total, preferably up to 14-membered.
  • Preferred hetero atoms are chosen from the group consisting of N, O and S.
  • the heteroaryl radical can preferably be chosen from the group consisting of pyrrolyl, indolyl, furyl (furanyl), benzofuranyl, thienyl (thiophenyl), benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzodioxolanyl, benzodioxanyl, benzoxazolyl, • benzoxadiazolyl, imidazothiazolyl, dibenzofuranyl, dibenzothienyl, phthalazinyl, pyrazolyl, imidazolyl, thiazolyl, oxadiazolyl, isoxazoyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, indazolyl, purinyl, indoliziny
  • Ci -6 -alkylene group includes acyclic saturated hydrocarbon radicals having 1 , 2, 3, 4, 5 or 6 C atoms, which can be branched- or straight-chain (unbranched) and unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different radicals and which link a corresponding radical to the main general structure.
  • the alkylene groups can preferably be chosen from the group consisting Of -CH 2 -, -CH 2 -CH 2 -, -CH(CH 3 )-, -CH 2 -CH 2 -CH 2 -, -CH(CH 3 )-CH 2 -, -CH(CH 2 CH 3 )-, -CH 2 -(CH 2 J 2 -CH 2 -, -CH(CHa)-CH 2 -CH 2 -, -CH 2 -CH(CH 3 )-CH 2 -, -CH(CH 3 )-CH(CH 3 )-, -CH(CH 2 CH 3 )-CH 2 -, -C(CH 3 J 2 -CH 2 -, -CH(CH 2 CH 2 CH 3 )-, -C(CH 3 )(CH 2 CH 3 )-, -CH 2 -(CH 2 )S-CH 2 -, -CH(CHa)-CH 2 -CH 2 -CH 2
  • C 2-6 -alkenylene group includes acyclic hydrocarbon radicals having 2, 3, 4, 5 or 6 C atoms, which are unsaturated once or several times, for example 2, 3 or 4 times, and can be branched- or straight-chain (unbranched) and unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different radicals and which link a corresponding radical to the main general structure.
  • C 2-6 -alkynylene group includes acyclic hydrocarbon radicals having 2, 3, 4, 5 or 6 C atoms, which are unsaturated once or several times, for example 2, 3 or 4 times, and can be branched- or straight-chain (unbranched) and unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different radicals and which link a corresponding radical to the main general structure.
  • aryl or heteroaryl bonded via a Ci_ 6 -alkylene group, C 2- 6-alkenylene group or C 2-6 -alkynylene group means that the Ci-e-alkylene groups, C 2-6 -alkenylene groups, C 2-8 -alkynylene groups and aryl or heteroaryl have the meanings defined above and the aryl or heteroaryl is bonded to the main general structure via a Ci- 6 -alkylene group, C 2 . 6 -alkenylene group or C 2-6 -alkynylene group.
  • Ci- 6 -alkylene group Ci- 6 -alkylene group
  • C 2 . 6 -alkenylene group or C 2-6 -alkynylene group There may be mentioned by way of example benzyl, phenethyl and phenylpropyl.
  • C 3 - ⁇ -cycloalkyl and heterocyclyl bonded via a Ci -6 -alkylene group, C 2-6 -alkenylene group or C 2-6 - alkynylene group means that the group, C 2- 6-alkenylene group, C 2 . 8-alkynylene group, C 3 - 8 -cycloalkyl and heterocyclyl have the meanings defined above and C 3- e-cycloalkyl and heterocyclyl are bonded to the main general structure via a group, C 2-6 -alkenylene group or C 2 - ⁇ -alkynylene group.
  • substituents for aryl and heteroaryl can be chosen from the group consisting of -O-C 1-3 -alkyl, unsubstituted d- ⁇ -alkyl, F, Cl, Br, I 1 CF 3 , OCF 3 , OH, SH, phenyl, naphthyl, furyl, thienyl and pyridinyl, in particular from the group consisting of F, Cl, Br, CF 3 , CH 3 and OCH 3 .
  • a hydrogen bonded to an N ring member can be replaced by a C ⁇ -alkyl, Cs- ⁇ -cycloalkyl, aryl, heteroaryl or a C 3-8 -cycloalkyl, aryl or heteroaryl bonded via a Ci -3 -alkylene group, wherein these alkyl, cycloalkyl, alkylene and aryl and heteroaryl groups can be unsubstituted or substituted as defined above.
  • substituted 3- to 8- membered heterocycloalkyl groups are i-methylpiperidin-4-yl, 1-phenylpiperidin- 4-yl, 1-benzylpiperidin-4-yl, 1-methylpyrrolidin-3-yl, 1-phenylpyrrolidin-3-yl, 1- benzylpyrrolin-3-yl, 1-methylazetidin-3-yl, 1-phenyl-azetidin-3-yl or 1- benzylazetidin-3-yl.
  • the substituents can be on one and/or more carbon ring atoms.
  • the term "substituted” is understood as meaning the corresponding substitution as defined for aryl and heteroaryl.
  • physiologically acceptable salt is understood as meaning preferably salts of the compounds according to the invention with inorganic or organic acids, which are physiologically acceptable - in particular when used on humans and/or mammals.
  • suitable acids are hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, citric acid, glutamic acid, 1 ,1-dioxo-1 ,2- dihydro1 ⁇ 6 -benzo[d]isothiazol-3-one (saccharic acid), monomethylsebacic acid, 5-oxo-proline, hexane-1 -sulfonic acid, nicotinic acid, 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethylbenzoic acid, ⁇ -liponic acid, acetylglycine, hippuric acid, phosphoric acid and/or aspartic acid.
  • the salts of hydrochloric acid (hydrochlorides) and of citric acid (citrates) are particularly preferred.
  • the radical R 1 represents phenyl, naphthyl, Indolyl, benzofuranyl, benzothiophenyl (benzothienyl); benzoxazolyl, benzoxadiazolyl, pyrrolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazothiazolyl, carbazolyl, dibenzofuranyl or dibenzothiophenyl (dibenzothienyl), benzyl or phenethyl, preferably phenyl, naphthyl, benzothiophenyl, benzoxadiazolyl, thiophenyl, pyridinyl, imidazothiazolyl or dibenzofuranyl, particularly preferably phenyl or naphthyl, in each case unsub
  • the radical R 1 represents phenyl or naphthyl, wherein the phenyl or naphthyl is unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different radicals chosen from the group consisting of methyl, methoxy, CF 3 , OCF 3 , F, Cl and Br.
  • the radical R 1 in the sulfonamide derivatives according to the invention is chosen from the group consisting of 4-methoxy- 2,3,6-trimethylphenyl, 4-methoxy-2,6-dimethylphenyl, 4-methoxy-2,3,5- trimethylphenyl, 2,4,6-trimethylphenyl, 2-chloro-6-methylphenyl, 2,4,6- trichlorophenyl, 2-chloro-6-(trifluoromethyl)phenyl, 2,6-dichloro-4-methoxyphenyl, 2-methylnaphthyl, 2-chloronaphthyl, 2-fluoronaphthyl, 2-chloro-4- (trifluoromethoxy)phenyl, 4-chloro-2,5-dimethylphenyl, 2,3-dichlorophenyl, 3,4- dichlorophenyl, 2-(trifluoromethyl)phenyl, 3-(trifluoromethyl)phenyl,
  • the radical R 1 in the sulfonamide derivatives according to the invention is chosen from the group consisting of 4-methoxy- 2,3,6-trimethylphenyl, 4-methoxy-2,6-dimethylphenyl, 4-methoxy-2,3,5- trimethylphenyl, 2,4,6-trimethylphenyl, 4-chloro-2,5-dimethylphenyl, 2,3- dichlorophenyl, 3,4-dichlorophenyl, 2-(trifluoromethyl)phenyl, 3- (trifluoromethyl)phenyl, 4-(trifluoromethyl)phenyl, 1-naphthyl and 2-naphthyl.
  • the radical R 1 in the sulfonamide derivatives according to the invention is 4-methoxy-2,6-dimethylphenyl, 3,4-dichlorophenyl, 4-chloro-2,5-methylphenyl or 2,4,6-trimethylphenyl, preferably 4-methoxy-2,6- dimethylphenyl.
  • p, q and r represent 1.
  • Q represents a single bond, CH 2 or -O-, preferably a single bond or -O-, n represents 0 or 1 and 0 represents 1.
  • R 4 and R 5 independently of one another represent H, substituted or unsubstituted C ⁇ -alky!, in particular methyl, ethyl, n-propyl, iso- propyl, n-butyl, sec-butyl, iso-butyl or t-butyl.
  • the group -NR 4 R 5 represents a ring of the type according to the general formula Na
  • R 8 represents H, Ci-e-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec- butyl, tert-butyl; or R 8 denotes aryl, preferably phenyl or naphthyl; or R 8 represents heteroaryl, preferably a 5- to 6-membered heteroaryl having 1 or 2 N hetero atoms, in particular 2-, 3- or 4-pyridinyl; or R 8 represents an aryl, preferably phenyl or naphthyl, bonded via a Ci -3 -alkylene group; or a heteroaryl, preferably a 5- to 6-membered heteroaryl having 1 or 2 N hetero atoms, in particular 2-, 3- or 4-pyridinyl, bonded via a Ci -3 -alkylene group.
  • halogen represents F, Cl, Br or I, preferably F.
  • s represents 0, 1 or 2, preferably 1 , wherein s is not 0 if X represents NR 8 .
  • the radicals Ci- 6 -alkyl, aryl and heteroaryl mentioned above in connection with R 8 can in each case be unsubstituted or substituted once or several times by identical or different radicals.
  • the aryl or heteroaryl can in each case be unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different substituents chosen from the group consisting of O-d -3 -alkyl, unsubstituted Ci- 6 -alkyl, F, Cl, Br, I, CF 3 , OCF 3 , OH and SH.
  • the ring according to the general formula Ha can represent one of the following groups: wherein R 13 represents one or, independently of one another, more substituents from the group H, F or Cl.
  • the group -NR 4 R 5 represents a ring of the type according to the general formula Hb:
  • s can be 0 or 1
  • two adjacent radicals R 21 , R 22 and R 23 together form a fused-on group of the type and the particular third radical from R 21 , R 22 and R 23 denotes H and denotes a single or double bond.
  • -NR 4 R 5 can represent one of the following groups:
  • the radical R 6 represents H, or d- ⁇ -alkyl; or R 6 represents an aryl, preferably phenyl, bonded via a Ci -3 -alkylene group.
  • the radicals Ci -6 -alkyl, Ci -3 -alkylene and aryl mentioned above in connection with R 6 can in each case be unsubstituted or substituted once or several times by identical or different radicals.
  • the aryl can in each case be unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different substituents chosen from the group consisting of O-Ci-3-alkyl, unsubstituted C 1-6 -alkyl, F, Cl 1 Br, I 1 CF 3 , OCF 3 , OH and SH.
  • the radical R 7 represents C- ⁇ - 6 -alkyl, in particular methyl, ethyl, propyl and iso-propyl, n-butyl, sec-butyl, iso-butyl or t-butyl; or R 7 represents C 4- 7-cycloalkyl, in particular cyclopentyl and cyclohexyl; or R 7 denotes aryl, in particular phenyl or naphthyl, or represents a 5- to 6-membered heteroaryl containing 1 to 3 hetero atoms from the group N, O, S, in particular 2-, 3- or 4-pyridinyl; or R 7 represents a C 4 - 6 -cycloalkyl, in particular cyclopentyl and cyclohexyl, bonded via a C 1-3 -alkylene group, an aryl, in particular phenyl or naphthyl,
  • the aryl or heteroaryl can in each case be unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different substituents chosen from the group consisting of O-Ci -3 -alkyl, unsubstituted Ci -6 - alkyl, F, Cl 1 Br, I 1 CF 3 , OCF 3 , OH and SH.
  • the radicals R 6 and R 7 form a ring of the type wherein the fused-on benzo group can in each case be unsubstituted or substituted at least once by substituents which, independently of one another, are chosen from the group consisting of Ci -6 -alkyl, Ci -6 -alkyl-O-, F, Cl, Br, I 1 CF 3 , OCF 3 , OH and SH.
  • R 2 represents H, Ci -6 -alkyl; C 3-8 -cycloalkyl, in particularly Cs- 6 -cycloalkyl, or R 2 represents aryl or heteroaryl; or R 2 represents a C 3-6 -cycloalkyl, aryl or heteroaryl bonded via a d -6 -alkylene group, C 2-6 - alkenylene group or C 2 - 6 -alkynylene group.
  • radicals C 1-6 -alkyl, C 3- 6-cycloalkyl, C 2 - 6 -a'kylene, C 2 - 6 -alkynylene, aryl and heteroaryl mentioned above in connection with R 2 can in each case be unsubstituted or substituted once or several times by identical or different radicals.
  • the aryl or heteroaryl can in each case be unsubstituted or substituted once or several times by identical or different radicals, wherein the radicals are chosen, for example, from the group consisting of Ci- 6 -alkyl, Ci -6 - alkyl-O-, F, Cl, Br, I, CF 3 , OCF 3 , OH and SH.
  • R 2 represents H, methyl, ethyl, propyl and /so-propyl; n-butyl, sec- butyl, iso-butyl, t-butyl or cyclopropyl; or R 2 denotes phenyl or 2-, 3- or 4- pyridinyl; or a cyclopropyl, phenyl or 2-, 3- or 4-pyridinyl bonded via a C 1-6 - alkylene group, wherein the phenyl or 2-, 3- or 4-pyridinyl is each case unsubstituted or substituted once or several times by identical or different radicals and the radicals are chosen from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF 3 , OCF 3 and OH.
  • R 3 represents H, d- ⁇ -alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl; or R 3 represents aryl or heteroaryl or an aryl or heteroaryl bonded via a Ci -6 -alkylene group, C 2-6 - alkenylene group or C 2-6 -alkynylene group.
  • radicals Ci -6 -alkyl, C 3 -6-cycloalkyl, C 2 - 6 -alkylene, C 2 - 6 -alkenylene, C 2 - 6 -alkynylene, aryl and heteroaryl mentioned above in connection with R 3 can in each case be unsubstituted or substituted once or several times by identical or different radicals.
  • the aryl or heteroaryl can in each case be unsubstituted or substituted once or several times by identical or different radicals, wherein the radicals are chosen from the group consisting of Ci -6 -alkyl, Ci -6 -alkyl-O-, F, Cl, Br, I, CF 3 , OCF 3 , OH and SH.
  • R 3 represents H, phenyl or 2-, 3- or 4-pyridinyl, wherein the phenyl or 2-, 3- or 4-pyridinyl is each case unsubstituted or substituted once or several times by identical or different radicals, wherein the radicals are chosen from the group consisting of methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, methoxy, F, Cl, Br, I, CF 3 , OCF 3 and OH.
  • R 2 represents H or methyl and R 3 represents H or phenyl, wherein phenyl is in each case unsubstituted or substituted once or several times by identical or different radicals, and the radicals are selected from the group consisting of methyl, methoxy, F, Cl, Br, I, CF 3 , OCF 3 and OH.
  • the heterocyclic ring formed by R 2 and R 3 is a saturated 4-, 5-, 6- or 7-membered heterocyclic ring which can be fused with an aryl or heteroaryl radical and, apart from the N atom to which R 2 is bonded, contains no further hetero atom.
  • the sulfonamide derivatives according to the invention are compounds according to the general formula Ia:
  • a, b and c independently of one another in each case represent 0 or 1 ;
  • R 9 , R 10 , R 11a , R 11b and R 11c independently of one another in each case represent H or two vicinal radicals from R 9 , R 10 , R 11a , R 11b and R 11c form a 5- or 6- membered fused-on aryl or heteroaryl radical, which can be unsubstituted or substituted once or several times by identical or different radicals.
  • the radicals R 1 , R 4 , R 5 , R 6 and R 7 as well as Q, n, o, p, q and r defined in the general formula Ia can likewise assume the particular specific meanings described above in connection with the preferred embodiments of the substituted sulfonamide derivatives according to the invention.
  • two of the vicinal radicals from R 9 , R 10 , R 11a , R 11b and R 11c form a fused-on benzene ring, which is unsubstituted or substituted once or several times, wherein the substituents are preferably chosen from the group consisting of methyl, methoxy, CF 3 , F, Cl and Br.
  • R represents the corresponding radical from R 11a , D R1 H1bD D a plausible preparationnd,1 D R > 1l 1I cC
  • substituted sulfonamide derivatives according to the invention are compounds having the general formula Ib
  • R 9 , R 10 , R 11a and R 11b independently of one another in each case represent H or two vicinal radicals from R 9 , R 10 , R 11a or R 11b form a 5- or 6-membered fused-on aryl or heteroaryl radical, preferably a fused-on benzene ring, which is unsubstituted or substituted once or several times, wherein the substituents are chosen from the group consisting of methyl, methoxy, CF 3 , F, Cl and Br.
  • radicals R 1 , R 4 , R 5 , R 6 and R 7 aswell as Q, n and o defined in the general formula Ib can likewise assume the particular specific meanings described above in connection with the preferred embodiments of the substituted sulfonamide derivatives according to the invention.
  • substituted sulfonamide derivatives have the general formula Ic
  • n 0, 1 or 2; preferably 0 or 1 o represents 1 , 2 or 3, preferably 1 ;
  • Q represents a single bond, -CH 2 - or -O-, preferably a single bond, or -O-;
  • R 1 represents aryl or heteroaryl or denotes an aryl or heteroaryl bonded via a Ci- 3 -alkylene group;
  • R 6 represents H, C- ⁇ - 6 -alkyl, or a C 3 - 8 cycloalkyl bonded via a Ci -3 -alkylene group, an aryl bonded via a Ci- 3 -alkylene group or a heteroaryl bonded via a Ci -3 - alkylene group,
  • R 7 represents Ci- 6 -alkyl, C ⁇ - ⁇ -alkenyl or C 2-6 -alkynyl, C 3-8 cycloalkyl, aryl or heteroaryl; or denotes a Cs- ⁇ -cycloalkyl, aryl or heteroaryl bonded via a C 1 - 6 - alkylene group,
  • d represents 0 or 1 and R 14 and R 15 together represent a fused-on unsubstituted or substituted aryl or heteroaryl radical;
  • R 8 represents H, Ci -6 -alkyl, C 3 - 8 cycloalkyl, aryl, heteroaryl or represents a C 3-8 - cycloalkyl, aryl or heteroaryl bonded via a Ci-6-alkylene group;
  • R 9 , R 10 , R 11a and R 11b independently of one another in each case represent H or two vicinal radicals from R 9 , R 10 , R 11a and R 11b form a 5- or 6-membered fused- on aryl or heteroaryl radical, which can be unsubstituted or substituted once or several times by identical or different radicals;
  • Ci -6 -alkyl, Ci -6 -alkylene, C 2-6 -alkenylene, C 2 - 6 -alkynylene, C 3-8 -cycloalkyl, aryl and heteroaryl can in each case be unsubstituted or substituted once or several times by identical or different radicals and the abovementioned radicals C 1-6 -alkyl, C 1-6 -alkylene, C 2-6 - alkenylene and C 2- 6-alkynylene can in each case be branched or unbranched;
  • the radicals defined in the general formula Ic 1 that is to say R 1 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11a and R 11b , and n and o in further embodiments can likewise assume the particular specific meanings described above in connection with the embodiments of the substituted sulfonamide derivatives according to the invention.
  • the substituted sulfonamide derivatives have the general formula Id
  • n 0, 1 or 2, preferably 0 or 1 , in particularly 1 ;
  • o represents 1 , 2 or 3, preferably 1 ;
  • Q represents a single bond, -O- or -CH 2 -, preferably a single bond or -O-;
  • X represents NR 8 or C(halogen) 2 ;
  • R 1 represents aryl or heteroaryl or denotes an aryl or heteroaryl bonded via a Ci. 3 -alkylene group
  • R 2 represents H, Ci -6 -alkyl, C 3-8 cycloalkyl, aryl or heteroaryl; or denotes a C 3-8 - cycloalkyl, aryl or heteroaryl bonded via a C ⁇ -alkylene group, C 2-6 -alkenylene group or C 2-6 -alkynylene group;
  • R 3 represents H, d- 6 -alkyl, aryl or heteroaryl; or denotes an aryl or heteroaryl bonded via a Ci- 6 -alkylene group, C 2-6 -alkenylene group or C 2-6 -alkynylene group;
  • R 6 represents H, Ci -6 -alkyl or a C 3-8 cycloalkyl bonded via a C- ⁇ - 3 -alkylene group, an aryl bonded via a Ci -3 -alkylene group or a heteroaryl bonded via a C 1-3 - alkylene group,
  • R 7 represents Ci -6 -alkyl, C 2 - 6 -alkenyl or C 2-6 -alkynyl, C 3-8 cycloalkyl, aryl or heteroaryl; or denotes a Qj- ⁇ -cycloalkyl, aryl or heteroaryl bonded via a Ci -6 - alkylene group,
  • d represents 0 or 1 and R 14 and R 15 together represent a fused-on unsubstituted or substituted aryl or heteroaryl radical;
  • R 8 represents H, Ci -6 -alkyl, C 3-8 -cycloalkyl, aryl, heteroaryl; or represents a C 3-8 - cycloalkyl, aryl or heteroaryl bonded via a Ci -6 -alkylene group;
  • Ci -6 -alkyl, Ci -6 -alkylene, C 2-6 -alkenylene, C 2 - 6 -alkynylene, C 3-8 -cycloalkyl, aryl and heteroaryl can in each case be unsubstituted or substituted once or several times by identical or different radicals and the abovementioned radicals Ci- 6 -alkyl, Ci- 6 -alkylene, C 2-6 - alkenylene and C 2 -e-alkynylene can in each case be branched or unbranched;
  • substituted aryl or heteroaryl is substituted once or several times by identical or different substituents chosen from the group consisting of F, Cl, Br, I, CN, NH 2 , NH-Ci- 6 -alkyl, NH-Ci -6 -alkylene-OH, N(Ci -6 -alkyl) 2 , N(C 1 , 6 -alkylene-OH) 2 , NH-aryl 1 , N(aryl 1 ) 2 , N(Ci.
  • radicals defined in the general formula Id that is to say R 1 , R 2 , R 3 , R 6 , R 7 and R 8 , and n and o in further embodiments can likewise assume the particular specific meanings described above in connection with the embodiments of the substituted sulfonamide derivatives according to the invention.
  • R 1 represents phenyl or naphthyl, wherein the phenyl or naphthyl is unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different radicals chosen from the group consisting of methyl, methoxy, CF 3 , OCF 3 , F, Cl and Br; in particular R 1 represents 4-methoxy-2,6- dimethylphenyl, 3,4-dichlorophenyl, 4-chloro-2,5-methylphenyl or 2,4,6- trimethylphenyl, preferably 4-methoxy-2,6-dimethylphenyl;.
  • R 2 represents H or methyl
  • R 3 represents H or phenyl, wherein phenyl is in each case unsubstituted or substituted once or several times by identical or different radicals, and the radicals are selected from the group consisting of methyl, methoxy, F, Cl 1 Br, I,
  • R 6 represents H, Ci -6 -alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl or tert-butyl.
  • R 7 represents Ci -6 -alkyl, in particular methyl, ethyl, propyl and iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, phenyl, naphthyl, 2-, 3- or 4-pyridinyl, benzyl or phenylethyl, wherein the aromatic or heteroaromatic groups can in each case be unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different substituents chosen from the group consisting of O-Ci -3 - alkyl, unsubstituted d -6 -alkyl, F, Cl, Br, I, CF 3 , OCF 3 , OH and SH;
  • R 8 represents H, Ci- 6 -alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, sec-butyl, tert-butyl; or R 8 represents phenyl, naphthyl, 2-, 3- or
  • 4-pyridinyl represents an aryl, preferably benzyl or phenylethyl, bonded via a
  • Ci -3 -alkylene group or represents a heteroaryl, preferably 2-, 3- or 4-pyridinyl, bonded via a Ci -3 -alkylene group; wherein the aryl or heteroaryl can in each case be unsubstituted or substituted once or several times, for example 2, 3, 4 or 5 times, by identical or different substituents chosen from the group consisting of O-C 1-3 -alkyl, unsubstituted C 1-6 -alkyl, F, Cl 1 Br, I 1 CF 3 , OCF 3 , OH and SH; and R 9 , R 10 , R 11a and R 11b independently of one another in each case represent H or two vicinal radicals from R 9 , R 10 , R 11a and R 11b , preferably R 9 and R 10 , form a benzo group, which can be unsubstituted or substituted once or several times, wherein the substituents are chosen from the group consisting of methyl, methoxy, CF 3
  • the sulfonamide derivatives according to the invention are chosen from the group consisting of:
  • the compounds according to the invention preferably have an antagonistic action on the human B1 R receptor or the B1 R receptor of the rat.
  • the compounds according to the invention have an antagonistic action both on the human B1 R receptor (hB1 R) and on the B1 R receptor of the rat (rB1 R).
  • Compounds which show an inhibition of at least 15 %, 25 %, 50 %, 70 %, 80 % or 90 % on the human B1 R receptor and/or on the B1 R receptor of the rat in the FLIPR assay at a concentration of 10 ⁇ m are particularly preferred.
  • Compounds which show an inhibition on the human B1 R receptor and on the B1R receptor of the rat of at least 70 %, in particular of at least 80 % and particularly preferably of at least 90 % at a concentration of 10 ⁇ m are very particularly preferred.
  • the agonistic or antagonistic action of substances can be quantified on the bradykinin 1 receptor (B1 R) of the human and rat species with ectopically expressing cell lines (CHO K1 cells) and with the aid of a Ca 2+ -sensitive dyestuff (Fluo-4) in a fluorescent imaging plate reader (FLIPR).
  • B1 R bradykinin 1 receptor
  • FLIPR fluorescent imaging plate reader
  • the figure in % activation is based on the Ca 2+ signal after addition of Lys-Des-Arg 9 -bradykinin (0.5 nM) or Des-Arg 9 -bradykinin (100 nM).
  • Antagonists lead to a suppression of the Ca 2+ inflow after addition of the agonist.
  • % inhibition compared with the maximum achievable inhibition is stated.
  • the substances according to the invention can act, for example, on the B1R relevant in connection with various diseases, so that they are suitable as a pharmaceutical active compound in medicaments.
  • the invention therefore also provides medicaments containing at least one substituted sulfonamide derivative according to the invention and optionally suitable additives and/or auxiliary substances and/or optionally further active compounds.
  • the medicaments according to the invention optionally contain, in addition to at least one substituted sulfonamide derivative according to the invention, suitable additives and/or auxiliary substances, that is to say also carrier materials, fillers, solvents, diluents, dyestuffs and/or binders, and can be administered as liquid medicament forms in the form of injection solutions, drops or juices or as semisolid medicament forms in the form of granules, tablets, pellets, patches, capsules, plasters/spray-on plasters or aerosols.
  • suitable additives and/or auxiliary substances that is to say also carrier materials, fillers, solvents, diluents, dyestuffs and/or binders, and can be administered as liquid medicament forms in the form of injection solutions, drops or juices or as semisolid medicament forms in the form of granules, tablets, pellets, patches, capsules, plasters/spray-on plasters or aerosols.
  • suitable additives and/or auxiliary substances that is to say also
  • Formulations in the form of tablets, coated tablets, capsules, granules, drops, juices and syrups are suitable for oral administration, and solutions, suspensions, easily reconstitutable dry formulations and sprays are suitable for parenteral, topical and inhalatory administration.
  • Sulfonamide derivatives according to the invention in a depot, in dissolved form or in a plaster, optionally with the addition of agents which promote penetration through the skin, are suitable formulations for percutaneous administration.
  • Formulation forms which can be used orally or percutaneously can release the substituted sulfonamide derivatives according to the invention in a delayed manner.
  • the substituted sulfonamide derivatives according to the invention can also be used in parenteral long-term depot forms, such as e.g. implants or implanted pumps.
  • parenteral long-term depot forms such as e.g. implants or implanted pumps.
  • other further active compounds known to the person skilled in the art can be added to the medicaments according to the invention.
  • the amount of active compound to be administered to patients varies as a function of the weight of the patient, the mode of administration, the indication and the severity of the disease. 0.00005 to 50 mg/kg, preferably 0.01 to 5 mg/kg of at least one substituted sulfonamide derivative according to the invention are conventionally administered.
  • a substituted sulfonamide derivative according to the invention contained therein is present as the pure diastereomer and/or enantiomer, as a racemate or as a non-equimolar or equimolar mixture of the diastereomers and/or enantiomers.
  • the substituted sulfonamide derivatives according to the invention can accordingly be used for the preparation of a medicament for treatment of pain, in particular acute, visceral, neuropathic or chronic pain.
  • the invention therefore also provides the use of a substituted sulfonamide derivative according to the invention for the preparation of a medicament for treatment of pain, in particular acute, visceral, neuropathic or chronic pain. Furthermore, the invention provides the use of a substituted sulfonamide derivative according to the invention for the preparation of a medicament for the treatment of inflammatory pain.
  • the invention also provide the use of a substituted sulfonamide derivative according to the invention for the preparation of a medicament for treatment of diabetes, diseases of the respiratory tract, for example bronchial asthma, allergies, COPD/chronic obstructive pulmonary disease or cystic fibrosis; inflammatory intestinal diseases, for example ulcerative colitis or CD/Crohn's disease; neurological diseases, for example multiple sclerosis or neurodegeneration; inflammations of the skin, for example atopic dermatitis, psoriasis or bacterial infections; rheumatic diseases, for example rheumatoid arthritis or osteoarthritis; septic shock; reperfusion syndrome, for example following cardiac infarction or stroke, obesity; and as an angiogenesis inhibitor.
  • diseases of the respiratory tract for example bronchial asthma, allergies, COPD/chronic obstructive pulmonary disease or cystic fibrosis
  • inflammatory intestinal diseases for example ulcerative colitis or CD/Crohn's disease
  • neurological diseases for example multiple
  • a substituted sulfonamide derivative which is used to be present as the pure diastereomer and/or enantiomer as a racemate or as a non-equimolar or equimolar mixture of the diastereomers and/or enantiomers.
  • the invention also provides a method for the treatment, in particular in one of the abovementioned indications, of a non-human mammal or a human requiring treatment of pain, in particular chronic pain, by administration of a therapeutically active dose of a substituted sulfonamide derivative according to the invention, or of a medicament according to the invention.
  • the invention also provides a process for the preparation of the substituted sulfonamide derivatives according to the invention as described in the following description, examples and claims.
  • the substituted sulfonamide derivatives according to the invention are prepared by the process described in the following (Method I) wherein the free amines (AM) and the carboxylic acids (AC) are reacted in an amide formation in the presence at least of an dehydrating agent and an organic base in an organic solvent to give the compounds (P) according to the invention.
  • Dehydrating agents which can be used are, for example, sodium sulfate or magnesium sulfate, phosphorus oxide or reagents such as, for example, CDI, DCC (optionally polymer-bonded), TBTU, EDCI, PyBOP or PFPTFA, also in the presence of HOAt or HOBt.
  • Organic bases which can be used are, for example, triethylamine, DIPEA or pyridine, and organic solvents which can be used are THF, methylene chloride, diethyl ether, dioxane, DMF or acetonitrile.
  • the temperature in the amide formation step (1) is preferably between O and 50 0 C.
  • the substituted sulfonamide derivatives according to the invention are prepared by the process described in the following (Method II) wherein amines (AM) are acylated with compounds of the type R 7 C(O)X to give the compounds (P*) according to the invention, wherein X represents a halide or a hydroxyl group.
  • the acylation reaction can be carried out, in particular, by reaction with carboxylic acids or carboxylic acid chlorides using dehydrating agents, such as, for example, sodium sulfate or magnesium sulfate, phosphorus oxide, or by addition of bases, such as, for example, sodium methanolate, triethylamine, diisopropylethylamine or N-methylmorpholine, and optionally coupling reagents, such as, for example, EDCI, HOBt, DCC (optionally polymer-bonded), CDI, HBTU, DMAP, PyBOP or pentafluorophenyl diphenyl phosphinate, in the presence of HOAt or HOBt in solvents, such as, for example, methanol, DMF, acetonitrile, dioxane, THF, diethyl ether or methylene chloride.
  • dehydrating agents such as, for example, sodium sulfate or magnesium sulfate, phosphorus
  • an organic or inorganic base for example potassium carbonate, sodium carbonate, sodium bicarbonate, diisopropylethylamine, trieth
  • the sulfonylated amino alcohols B are reacted in an alkylation reaction with halogenated ester derivatives, using tetrabutylammonium chloride or bromide or tetrabutylammonium hydrogen sulfate, in a phase transfer reaction using an organic solvent, such as THF, toluene, benzene or xylene, and an inorganic base, such as potassium hydroxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, or in the presence of an organic or inorganic base
  • conventional inorganic bases are metal alcoholates, such as sodium methanolate, sodium ethanolate, potassium tert-butylate, lithium bases or sodium bases, such as lithium diisopropylamide, butyllithium, terf-butyllithium, sodium methylate, or metal hydrides, such as potassium hydride, lithium hydride, sodium hydride, conventional organic bases are diisopropylethylamine,
  • an organic or inorganic base for example potassium carbonate, sodium bicarbonate, diisopropylethylamine, triethylamine,
  • mesylates or alternative alkylating reagents optionally in the presence of an organic or inorganic base, for example sodium hydride, potassium carbonate, caesium carbonate, DBU or DIPEA, preferably in an organic solvent,
  • the ester derivatives C are reacted in an ester cleavage using organic acids, such as trifluoroacetic acid, or aqueous inorganic acids, such as hydrochloric acid, or using aqueous inorganic bases, such as lithium hydroxide, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, in organic solvents, such as methanol, dioxane, methylene chloride, THF, diethyl ether or these solvents as mixtures, at 0 0 C to room temperature, to give the acid stages of the general formula D.
  • organic acids such as trifluoroacetic acid, or aqueous inorganic acids, such as hydrochloric acid
  • aqueous inorganic bases such as lithium hydroxide, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate
  • organic solvents such as methanol, dioxane, methylene chloride, THF, diethyl ether
  • the racemic (R and S configuration) or enantiomerically pure (R or S configuration) amino acid esters A are converted by a reduction into an amino alcohol B using metal hydrides as reducing agents, such as, for example, LiAIH 4 , BH 3 x DMS or NaBH 4 , in an organic solvent, such as THF or diethyl ether, at temperatures of from 0 0 C to the reflux temperature.
  • metal hydrides as, for example, LiAIH 4 , BH 3 x DMS or NaBH 4
  • an organic or inorganic base for example potassium carbonate, sodium bicarbonate, diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine, diethylamine or DBU, preferably in
  • the sulfonylated amino alcohols C are reacted in an alkylation reaction with halogenated ester derivatives, using tetrabutylammonium chloride or bromide or tetrabutylammonium hydrogen sulfate, in a phase transfer reaction using an organic solvent, such as THF 1 toluene, benzene or xylene, and an inorganic base, such as potassium hydroxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, or in the presence of an organic or inorganic base
  • conventional inorganic bases are metal alcoholates, such as sodium methanolate, sodium ethanolate, potassium tert-butylate, lithium bases or sodium bases, such as lithium diisopropylamide, butyllithium, te/t-butyllithium, sodium methylate, or metal hydrides, such as potassium hydride, lithium hydride, sodium hydride, conventional organic bases are diisopropylethyl
  • 3-(pyridin-2-yl)acrylic acid E is esterified using dehydrating reagents, for example inorganic acids, such as H 2 SO 4 or phosphorus oxides, or organic reagents, such as thionyl chloride, in organic solvents, such as THF, diethyl ether, methanol, ethanol or methylene chloride, to give stage F, at temperatures of from room temperature to the reflux temperature.
  • dehydrating reagents for example inorganic acids, such as H 2 SO 4 or phosphorus oxides, or organic reagents, such as thionyl chloride, in organic solvents, such as THF, diethyl ether, methanol, ethanol or methylene chloride, to give stage F, at temperatures of from room temperature to the reflux temperature.
  • organic solvents such as THF, diethyl ether, methanol, ethanol or methylene chloride
  • an organic or inorganic base for example potassium carbonate, sodium bicarbonate, diisopropylethylamine, triethylamine, pyridine, diethylamine or DBU, preferably in an organic solvent, for example acetonitrile, methylene chloride or tetrahydrofuran, at
  • the ester derivatives D and I are reacted in an ester cleavage using organic acids, such as trifluoroacetic acid, or aqueous inorganic acids, such as hydrochloric acid, or using aqueous inorganic bases, such as lithium hydroxide, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, in organic solvents, such as methanol, dioxane, methylene chloride, THF, diethyl ether or these solvents as mixtures, at 0 0 C to room temperature, to give the acid stages of the general formula J.
  • organic acids such as trifluoroacetic acid
  • aqueous inorganic acids such as hydrochloric acid
  • aqueous inorganic bases such as lithium hydroxide, potassium hydroxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate
  • organic solvents such as methanol, dioxane, methylene chloride, THF, diethyl
  • the protected piperidone employed can be converted into the nitrile by addition of an amine and a source of cyanide.
  • the reaction can be carried out in one or two stages, as is known to the person skilled in the art.
  • a nitrile alcohol is first formed and isolated.
  • the nitrile alcohol can be formed by reaction of the protected piperidone with HCN, KCN or NaCN.
  • Typical solvents are water, methanol, ethanol, THF, piperidine, diethyl ether or a mixture of these solvents. If NaCN and KCN are used, the cyanide required can typically be liberated by addition of, for example, sodium hydrogen sulfite, sulfuric acid, acetic acid or hydrochloric acid.
  • Trimethylsilyl cyanide for example, is likewise suitable as a source of nitrile.
  • the cyanide can be liberated, for example, by boron trifluoride etherate,
  • Typical solvents are water or toluene.
  • (Cyano-C)diethylaluminium for example, is suitable as a further source of cyanide.
  • THF, toluene or a mixture of the two solvents can be used as the solvent.
  • the reaction temperature can be between -78 0 C and +25 0 C for all the variants.
  • Alcohols such as methanol or ethanol, are particularly suitable as the solvent for the reaction of the nitrile alcohol with the amine.
  • the reaction temperature can be between 0 0 C and +25 0 C.
  • the nitrile alcohol primarily formed is formed in situ and reacted with the amine.
  • the reduction of the nitrile group can be carried out with the aid of reducing agents or by catalytic hydrogenation.
  • Suitable reducing agents are, for example, lithium aluminium hydride, aluminium hydride or sodium, in solvents, such as, for example, THF, diethyl ether, dioxane or ethanol.
  • the catalytic hydrogenation can be carried out by means of catalysts, such as, for example, platinum, platinum(IV) oxide or Raney nickel, in solvents, such as ethanol, methanol, optionally with the addition of ammonia or aqueous
  • the subsequent acylation reaction of the amine can be carried out by reaction with carboxylic acids or carboxylic acid chlorides using dehydrating agents, such as, for example, sodium sulfate or magnesium sulfate, phosphorus oxide, or by addition of bases, such as, for example, sodium methanolate, triethylamine, diisopropylethylamine or N-methylmorpholine, and optionally coupling reagents, such as, for example, EDCI, HOBt, DCC (optionally polymer-bonded), CDI,
  • dehydrating agents such as, for example, sodium sulfate or magnesium sulfate, phosphorus oxide
  • bases such as, for example, sodium methanolate, triethylamine, diisopropylethylamine or N-methylmorpholine
  • coupling reagents such as, for example, EDCI, HOBt, DCC (optionally polymer-bonded), CDI,
  • HBTU HBTU
  • DMAP PyBOP
  • pentafluorophenyl diphenyl phosphinate in the presence of HOAt or HOBt in solvents, such as, for example, methanol, DMF, acetonitrile, dioxane, THF, diethyl ether or MC.
  • solvents such as, for example, methanol, DMF, acetonitrile, dioxane, THF, diethyl ether or MC.
  • the reaction time can vary between 1 h and 3 d.
  • the method for splitting off of the protective groups depends on the nature of the protective group used.
  • carbamates such as, for example, the Boc, Fmoc or Cbz(Z) protective group, or also benzylic protective groups are suitable.
  • the BOC protective group can be split off, for example, by reaction with HCI in organic solvents, such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate, or by reaction with TFA or methanesulfonic acid in methylene chloride or THF at a temperature of from O 0 C to 110 0 C over a reaction time of 0.5 - 20 h.
  • the Cbz protective group can be split off, for example, under acidic conditions. This acidic splitting off can be carried out, for example, by reaction with an HBr/glacial acetic acid mixture, a mixture of TFA in dioxane/water or HCI in methanol or ethanol.
  • reagents such as, for example, Me 3 SiI, in solvents, such as, for example, MC, chloroform or acetonitrile, BF 3 etherate with the addition of ethanethiol or M ⁇ 2 S, in solvents, such as, for example, MC, a mixture of aluminium chloride/anisole in a mixture of MC and nitromethane, or triethylsilane/PdCI 2 in methanol, with the addition of triethylamine, are also suitable.
  • solvents such as, for example, MC, chloroform or acetonitrile, BF 3 etherate with the addition of ethanethiol or M ⁇ 2 S
  • solvents such as, for example, MC, a mixture of aluminium chloride/anisole in a mixture of MC and nitromethane, or triethylsilane/PdCI 2 in methanol, with the addition of triethylamine
  • a further method is the hydrogenolytic splitting off of the protective group under increased pressure or normal pressure with the aid of catalysts, such as, for example, Pd on charcoal, Pd(OH)2, PdCI 2 , Raney nickel or PtO 2 , in solvents, such as, for example, methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCI, formic acid or TFA.
  • the Fmoc protective group is as a rule split off under basic conditions in solvents, such as, for example, acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, MC or chloroform.
  • Suitable bases are, for example, diethylamine, piperidine, 4-aminomethylpiperidine, pyrrolidine, DBU, NaOH or LiOH.
  • reagents such as, for example, Ag 2 O/Mel can also be used.
  • a benzylic protective group can be split off, for example, by catalytic hydrogenation.
  • Suitable catalysts are, for example, Pd on charcoal, PtO 2 or Pd(OH) 2 .
  • the reaction can be carried out in solvents, such as, for example, ethanol, methanol, 2-propanol, acetic acid, THF or DMF, with the addition of acids, such as, for example, ammonium formate, maleic acid or formic acid, or in mixtures of the solvents.
  • the amine function for instance the primary amine function, is protected with the aid of a protective group.
  • Protective groups which differ from the protective group on the piperidine nitrogen are suitable in this step.
  • carbamates such as, for example, the Boc, Fmoc or Cbz(Z) protective group, or a benzylic protective group are suitable.
  • the introduction of the BOC protective group by means of di-tert-butyl dicarbonate can be carried out in solvents, such as, for example, dioxane, MC, THF, DMF, water, benzene, toluene, methanol, acetonitrile or mixtures of these solvents, optionally with the addition of sodium hydroxide, triethylamine, diisopropylethylamine, sodium bicarbonate, sodium carbonate or DMAP, at temperatures of between 0 0 C and 100 0 C.
  • solvents such as, for example, dioxane, MC, THF, DMF, water, benzene, toluene, methanol, acetonitrile or mixtures of these solvents, optionally with the addition of sodium hydroxide, triethylamine, diisopropylethylamine, sodium bicarbonate, sodium carbonate or DMAP, at temperatures of between 0 0 C and 100 0 C.
  • the Fmoc protective group is introduced by reaction of 9H-fluoren-9-ylmethyl chloroformate in solvents, such as, for example, MC, DCE, diethyl ether, THF, dioxane, acetone, acetonitrile, DMF or water, optionally with the addition of a base, such as, for example, diisopropylethylamine, triethylamine, pyridine, N- methylmorpholine, sodium carbonate or sodium bicarbonate, and optionally under irradiation with microwaves.
  • solvents such as, for example, MC, DCE, diethyl ether, THF, dioxane, acetone, acetonitrile, DMF or water
  • a base such as, for example, diisopropylethylamine, triethylamine, pyridine, N- methylmorpholine, sodium carbonate or sodium bicarbonate, and optionally under irradiation with microwaves.
  • the Cbz protective group can be introduced by reaction of chloroformic acid benzyl ester in solvents, such as, for example, diethyl ether, THF, DMF, benzene, toluene, dioxane, water, acetone, ethyl acetate, MC or chloroform, optionally with the addition of a base, such as, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide or triethylamine, optionally with the addition of a coupling reagent, such as, for example, HOBt.
  • the benzylic protective groups can be introduced by alkylation by means of chloro- or bromobenzyl compounds or by reductive amination with benzaldehydes.
  • the alkylation can be carried out in solvents, such as, for example, ethanol, methanol, water, acetonitrile, MC, THF, DMSO, water or mixtures of these solvents.
  • solvents such as, for example, ethanol, methanol, water, acetonitrile, MC, THF, DMSO, water or mixtures of these solvents.
  • a base such as, for example, diethylamine, sodium bicarbonate, sodium carbonate, potassium carbonate or caesium carbonate, and if appropriate an auxiliary reagent, such as, for example, potassium iodide or sodium iodide, must be added.
  • the reductive amination is carried out in solvents, such as, for example, methanol, ethanol, DCE or MC.
  • Suitable reducing agents are, for example, sodium cyanoborohydride or sodium triacetoxyborohydride, optionally with the addition of acetic acid.
  • a trifluoroacetyl protecting group (CF 3 CO) can be introduced by reaction of the amine with trifluoroacetic anhydride in the presence of a suitable base, such as for example triethylamine or H ⁇ nig base, in a suitable solvent such as dichloromethane, THF, chloroform or mixtures thereof.
  • a suitable base such as for example triethylamine or H ⁇ nig base
  • a suitable solvent such as dichloromethane, THF, chloroform or mixtures thereof.
  • the protective group on the piperidine nitrogen is split off.
  • the method for splitting off of the protective groups depends on the nature of the protective group used. For example, carbamates, such as, for example, the Boc, Fmoc or Cbz(Z) protective group, or also benzylic protective groups are suitable.
  • the BOC protective group can be split off, for example, by reaction with HCI in organic solvents, such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate, or by reaction with TFA or methanesulfonic acid in methylene chloride or THF at a temperature of from 0 0 C to 110 0 C over a reaction time of 0.5 - 20 h.
  • the Cbz protective group can be split off, for example, under acidic conditions.
  • This acidic splitting off can be carried out, for example, by reaction with an HBr/glacial acetic acid mixture, a mixture of TFA in dioxane/water or HCI in methanol or ethanol.
  • reagents such as, for example, Me 3 SiI, in solvents, such as, for example, MC, chloroform or acetonitrile, BF 3 etherate with the addition of ethanethiol or Me 2 S, in solvents, such as, for example, MC, a mixture of aluminium chloride/anisole in a mixture of MC and nitromethane, or triethylsilane/PdCI 2 in methanol, with the addition of triethylamine, are also suitable.
  • solvents such as, for example, MC, chloroform or acetonitrile, BF 3 etherate with the addition of ethanethiol or Me 2 S
  • solvents such as, for example, MC, a mixture of aluminium chloride/anisole in a mixture of MC and nitromethane, or triethylsilane/PdCI 2 in methanol, with the addition of triethylamine
  • a further method is the hydrogenolytic splitting off of the protective group under increased pressure or normal pressure with the aid of catalysts, such as, for example, Pd on charcoal, Pd(OH) 2 , PdCI 2 , Raney nickel or PtO 2 , in solvents, such as, for example, methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCI, formic acid or TFA.
  • catalysts such as, for example, Pd on charcoal, Pd(OH) 2 , PdCI 2 , Raney nickel or PtO 2
  • solvents such as, for example, methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCI, formic acid or TFA.
  • the Fmoc protective group is as a rule split off under basic conditions in solvents, such as, for example, acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, MC or chloroform.
  • solvents such as, for example, acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, MC or chloroform.
  • Suitable bases are, for example, diethylamine, piperidine, 4-aminomethylpiperidine, pyrrolidine, DBU, NaOH or LiOH.
  • reagents such as, for example, Ag 2 ⁇ /Mel can also be used.
  • a benzylic protective group can be split off, for example, by catalytic hydrogenation.
  • Suitable catalysts are, for example, Pd on charcoal, PtO 2 or Pd(OH) 2 .
  • the reaction can be carried out in solvents, such as, for example, ethanol, methanol, 2-propanol, acetic acid, THF or DMF, with the addition of acids, such as, for example, ammonium formate, maleic acid or formic acid, or in mixtures of the solvents.
  • solvents such as, for example, ethanol, methanol, 2-propanol, acetic acid, THF or DMF
  • acids such as, for example, ammonium formate, maleic acid or formic acid, or in mixtures of the solvents.
  • the subsequent acylation reaction of the amine can be carried out by reaction with carboxylic acids or carboxylic acid chlorides using dehydrating agents, such as, for example, sodium sulfate or magnesium sulfate, phosphorus oxide, or by addition of bases, such as, for example, sodium methanolate, triethylamine, diisopropylethylamine or N-methylmorpholine, and optionally coupling reagents, such as, for example, EDCI, HOBt, DCC (optionally polymer-bonded), CDI, HBTU, DMAP, PyBOP or pentafluorophenyl diphenyl phosphinate, in the presence of HOAt or HOBt in solvents, such as, for example, methanol, DMF, acetonitrile, dioxane, THF, diethyl ether or MC.
  • the reaction time can vary between 1 h and 3 d.
  • the second protective group is then split off.
  • the method for splitting off of the protective groups depends on the nature of the protective group used. For example, carbamates, such as, for example, the Boc, Fmoc or Cbz(Z) protective group, or also benzylic protective groups are suitable.
  • the BOC protective group can be split off, for example, by reaction with HCI in organic solvents, such as dioxane, methanol, ethanol, acetonitrile or ethyl acetate, or by reaction with TFA or methanesulfonic acid in methylene chloride or THF at a temperature of from O 0 C to 110 0 C over a reaction time of 0.5 - 20 h.
  • the Cbz protective group can be split off, for example, under acidic conditions. This acidic splitting off can be carried out, for example, by reaction with an HBr/glacial acetic acid mixture, a mixture of TFA in dioxane/water or HCI in methanol or ethanol.
  • reagents such as, for example, Me 3 SiI, in solvents, such as, for example, MC, chloroform or acetonitrile, BF 3 etherate with the addition of ethanethiol or Me 2 S, in solvents, such as, for example, MC, a mixture of aluminium chloride/anisole in a mixture of MC and nitromethane, or triethylsilane/PdCI 2 in methanol, with the addition of triethylamine, are also suitable.
  • solvents such as, for example, MC, chloroform or acetonitrile, BF 3 etherate with the addition of ethanethiol or Me 2 S
  • solvents such as, for example, MC, a mixture of aluminium chloride/anisole in a mixture of MC and nitromethane, or triethylsilane/PdCI 2 in methanol, with the addition of triethylamine
  • a further method is the hydrogenolytic splitting off of the protective group under increased pressure or normal pressure with the aid of catalysts, such as, for example, Pd on charcoal, Pd(OH) 2 , PdCI 2 , Raney nickel or PtO 2 , in solvents, such as, for example, methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCI, formic acid or TFA.
  • catalysts such as, for example, Pd on charcoal, Pd(OH) 2 , PdCI 2 , Raney nickel or PtO 2
  • solvents such as, for example, methanol, ethanol, 2-propanol, THF, acetic acid, ethyl acetate, chloroform, optionally with the addition of HCI, formic acid or TFA.
  • the Fmoc protective group is as a rule split off under basic conditions in solvents, such as, for example, acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, MC or chloroform.
  • solvents such as, for example, acetonitrile, DMF, THF, diethyl ether, methanol, ethanol, 1-octanethiol, MC or chloroform.
  • Suitable bases are, for example, diethylamine, piperidine, 4-aminomethylpiperidine, pyrrolidine, DBU, NaOH or LiOH.
  • reagents such as, for example, Ag 2 O/Mel can also be used.
  • a benzylic protective group can be split off, for example, by catalytic hydrogenation.
  • Suitable catalysts are, for example, Pd on charcoal, PtO 2 or Pd(OH) 2 .
  • the reaction can be carried out in solvents, such as, for example, ethanol, methanol, 2-propanol, acetic acid, THF or DMF, with the addition of acids, such as, for example, ammonium formate, maleic acid or formic acid, or in mixtures of the solvents.
  • solvents such as, for example, ethanol, methanol, 2-propanol, acetic acid, THF or DMF
  • acids such as, for example, ammonium formate, maleic acid or formic acid, or in mixtures of the solvents.
  • CF 3 CO trifluoroacetyl protecting group
  • a suitable base such as for example potassium carbonate or lithium hydroxide
  • a suitable solvent such as methanol, ethanol, water or mixtures thereof.
  • the reductive amination is carried out by reaction of aldehydes with amines and subsequent reduction with reducing agents, such as, for example, NaBH(OAc) 3 , NaBH 4 , LiBH 3 CN, NaBH 3 CN, borane-pyridine complex or ⁇ - picoline-borane complex, in solvents, such as, for example, ethanol, methanol, MC, DCE, THF, DMF, benzene, toluene or mixtures of these solvents, optionally with the addition of acids, such as, for example, HCI or acetic acid.
  • reducing agents such as, for example, NaBH(OAc) 3 , NaBH 4 , LiBH 3 CN, NaBH 3 CN, borane-pyridine complex or ⁇ - picoline-borane complex
  • solvents such as, for example, ethanol, methanol, MC, DCE, THF, DMF, benzene, toluene or mixtures of these solvents,
  • the aldehyde can be reacted with a corresponding amine to give the imine, optionally with the addition of dehydrating agents, and then converted into the amine by catalytic hydrogenation.
  • Suitable catalysts are, for example, Pt 2 O, Pd on charcoal or Raney nickel, in solvents, such as, for example, ethanol or methanol.
  • organic bases such as diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine, diethylamine or DBU, or an inorganic base, for example
  • the chemicals and solvents employed were obtained commercially from the conventional suppliers (e.g. Acros, Avocado, Aldrich, Bachem, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI etc.) or synthesized by the methods known to the person skilled in the art.
  • Stage 1 A solution of 3,5-dimethylanisole (102.5 g, 753 mmol) in MC (1 I) was cooled to 0 0 C. A solution of chlorosulfonic acid (251 ml, 3,763 mmol) in MC (250 ml) was added dropwise to this solution. After a reaction time of 10 min, the reaction solution was introduced into an ice bath (1 1), the phases were separated and extraction was carried out once more with MC (250 ml). The combined organic phases were washed with water (1 I) and sat. NaCI solution (1 I), dried over Na 2 SO 4 and concentrated. The product was purified by column chromatography over silica gel (heptane/MC 5:1). Yield: 63.5g, 36 %.
  • Triethylamine 80 mmol was added to a solution of the amino alcohol (35 mmol) in MC (200 ml) and the mixture was cooled to 0 0 C using an ice bath. The sulfonyl chloride (32 mmol) was then added and the mixture was stirred at RT for 3 h. After addition of 0.5 M HCI (100 ml), the organic phase was separated off, washed with water, dried over Na 2 SO 4 and filtered and the solvent was removed in vacuo. The crude product was used in the next stage without further purification.
  • n-Bu 4 NCI (10 mmol) was added to a solution of the product from stage 2. (30 mmol) in toluene (125 ml). The mixture was cooled to 0 0 C, and first aqueous 35 % strength NaOH (150 ml) and then bromoacetic acid tert-butyl ester (45 mmol) in toluene (25 ml) were added dropwise. The reaction mixture was stirred for 3 h and then washed neutral with water and dried with Na 2 SO 4 and the organic solvent was removed in vacuo. The crude product was used in the next stage without further purification.
  • Stage 4 The product from stage 3. (20 mmol) was dissolved in 4 N hydrochloric acid in dioxane (80 ml) and the solution was stirred at RT overnight. The solvent was largely distilled off and the crude product was purified by recrystallization.
  • the aqueous phase was then cautiously acidified with HCI (1 N) and extracted with ethyl acetate.
  • the organic phase was washed with water and sat. NaCI solution and dried over Na 2 SO 4 . After removal of the solvent, the product was obtained in an adequate purity.
  • aqueous phase was extracted once more with ethyl acetate (100 ml) and the combined organic phases were washed with sat. NaCI solution (500 ml), dried over Na 2 SO 4 and concentrated. Yield. 9.4 g, 97 %.
  • Stage 4 Aqueous NaOH solution (6 M, 100 ml) was added to a solution of methyl 3-(1-(4-chloro-2,5-dimethylphenylsulfonyl)piperidin-2-yl)propionate (12.82 g, 34.3 mmol) in THF (100 ml). After a reaction time of 1 h, the solvent was removed on a rotary evaporator and the residue was cooled to 0 0 C. HCI (6 M, 100 ml) was added and the mixture was extracted with ethyl acetate. The organic phase was dried over Na 2 SO 4 and concentrated. Yield: 12.36 g, 100%.
  • Stage 1 Triethylamine (125 mmol) was added to a solution of the amino alcohol (100 mmol) in MC (200 ml) and the mixture was cooled to 0 0 C using an ice bath. The sulfonyl chloride (50 mmol) was then added as a solution in MC (100 ml) and the mixture was stirred at RT for 3 h. After addition of 0.5 M hydrochloric acid (100 ml), the organic phase was separated off, washed with water, dried over Na 2 SO 4 and filtered and the solvent was removed in vacuo. The crude product was used in the next stage without further purification. Stage 2.
  • n-Bu 4 NCI (10 mmol) was added to a solution of the product from stage 1 (31 mmol) in toluene (200 ml), the mixture was cooled to 0 0 C and first aqueous 35 % strength NaOH (200 ml) and then bromoacetic acid tert-butyl ester (46 mmol) were added dropwise. The reaction mixture was stirred for 3 h and then washed neutral with water and dried with Na 2 SO 4 and the organic solvent was removed in vacuo. The crude product was purified by column chromatography (silica gel, heptane / ethyl acetate, 3:1).
  • Stage 1 1 ,2,3,4-Tetrahydroquinoline-2-carboxylic acid ethyl ester (25 mmol) in THF (5 ml/mol) was added dropwise to a suspension of LAH (2 eq.) in THF (50 ml) at O 0 C. The reaction mixture was stirred at RT for 1 h and then heated under reflux for 4 h. After addition of aqueous sat. Na 2 SO 4 solution, the mixture was filtered and the organic solvent was removed in vacuo. The product was purified via column chromatography (3:7 ethyl acetate/hexane). Yield: 50 %. Stage 2.
  • Stage 3 A solution of the sulfonamide (16 mmol) dissolved in THF (100 ml) was added dropwise to a suspension, cooled to O 0 C, of NaH (2 eq.) in THF (300 ml), while stirring. After stirring for 45 min at this temperature, a solution of bromoacetic acid terf-butyl ester (1.5 eq.) in THF (50 ml) was added. The reaction mixture was heated at 50 0 C for 20 h. It was then cooled to 0 0 C, ice was added and the mixture was extracted with ethyl acetate. The organic phase was washed with aqueous sat. NaCI solution and dried over Na 2 SO 4 .
  • Step-1 2-(Cyclopropylamino)ethanol
  • Step-2 N-Cyclopropyl-N-(2-hydroxyethyl)-4-methoxy-2,6- dimethylbenzenesulfonamide
  • Step-3 tert-Butyl 2-(2-(N-cyclopropyl-4-methoxy-2,6- dimethylphenylsulfonamido)ethoxy)acetate
  • Step-4 2-(2-(N-Cyclopropyl-4-methoxy-2,6- dimethylphenylsulfonamido)ethoxy)acetic acid (AC7)
  • Carboxylic acid AC8 was synthesised in analogy to carboxylic acid AC7 (2-(2- (N-cyclopropyl-4-methoxy-2,6-dimethylphenylsulfonamido)ethoxy)acetic acid).
  • Carboxylic acid AC9 was synthesised in analogy to carboxylic acid AC7 (2-(2- (N-cyclopropyl-4-methoxy-2,6-dimethylphenylsulfonamido)ethoxy)acetic acid).
  • Step-2 (S)-(1-(4-Methoxy-2,6-dimethylphenylsulfonyl)indolin-2-yl)methanol
  • Step-3 (S)-tert-Butyl 2-((1 -(4-methoxy-2,6-dimethylphenylsulfonyl)indolin- 2-yl)methoxy)acetate
  • Step-4 (S)-2-((1-(4-Methoxy-2,6-dimethylphenylsulfonyl)indolin-2- yl)methoxy)acetic acid (AC10)
  • AC10 acetic acid
  • TFA TFA
  • tert-Butyl ester 5 (10.9 g, 24.68 mmol) was dissolved in CH 2 CI 2 (150 ml_). TFA (75 mL) was added and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated in vacuo and co-evaporated with toluene (3x) and CH 2 CI 2 (3x).
  • ester 5 (12.90 g, 29.2 mmol) in THF (95 ml.) and MeOH (95 mL) was added aqueous 6 M NaOH (95 ml_). After 1 h organic solvents were evaporated and aqueous 6 M HCI (95 mL) was added at 0 0 C. The mixture was extracted with EtOAc (500 mL), dried (Na 2 SO 4 ) and co-evaporated with Et 2 O (2 x) to afford compound 6 (11.07 g, 98%).
  • Stage 1 Water (1.2 ml), the corresponding amine (52.9 mmol), acetic acid (52.9 mmol) and potassium cyanide (58.2 mmol) were added successively to a solution of N-benzylpiperidone (52.9 mmol) in methanol (20 ml). The reaction mixture was stirred at room temperature for 1 h, a white solid forming. NH 4 OH solution (35 %, 300 ml) and ice (100 g) were then added to the reaction solution. The solid formed was filtered off, washed several times with water and dried. Stage 2.
  • the crude product was purified by column chromatography (neutral AI 2 Oa), MC/methanol: 9 :1). Stage 4. Pd(OH) 2 (10 %, 50 wt.%) was added to a solution of the benzylated compound in methanol (3 ml/mmol) and hydrogenolysis was carried out under atmospheric pressure for 16 h (LCMS control). When the reaction was concluded, the reaction mixture was filtered over Celite and the residue was rinsed a few times with methanol. The combined organic phases were concentrated under reduced pressure. The crude product was used further without further purification.
  • the amine units AM1-AM5 listed in the following were prepared by Method A.
  • stage 1. and stage 2. were carried out analogously to Method A.
  • Stage 3 The benzyl-protected amine (1 eq.) was dissolved in MC (5 ml/mmol), DIPEA (1.5 eq.) and BoC 2 O (1.2 eq.) were added at 25 0 C and the mixture was stirred at this temperature for 16 h (TLC control). The mixture was diluted with MC and then washed first with water and then with NaCI solution. The organic phase was dried over Na 2 SO 4 and concentrated. The crude product was purified by column chromatography (silica gel, MC/methanol: 97 : 3). Stage 4.
  • Stage 6 The Boc-protected amines from stage 5. were dissolved in TFA (20 % in MC, 5 ml/mmol) at 0 0 C and the solution was then warmed to 25 0 C. The reaction mixture was stirred at this temperature for 3 h (TLC control). When the reaction was concluded, the solvent was removed completely and the crude product was used for the further reactions without further purification.
  • Step-1 1-Benzyl-4-(4-cyclopropylpiperazin-1-yl)piperidine-4-carbonitrile
  • Step-2 (1 -Benzyl-4-(4-cyclopropylpiperazin-1 -yl)piperidin-4- yl)methanamine
  • Step-3 N-((1 -Benzyl-4-(4-cyciopropylpiperazin-1 -yl)piperidin-4-yl)methyl)- 2,2,2-trifluoroacetamide
  • Step-4 N-((4-(4-Cyclopropylpiperazin-1-yl)piperidin-4-yl)methyl)-2,2,2- trifluoroacetamide
  • Step-6 tert-Butyl 4-(aminomethyl)-4-(4-cyclopropylpiperazin-1- yl)piperidine-1 -carboxylate
  • Step-7 tert-Butyl 4-(4-cyclopropylpiperazin-1-yl)-4- (isonicotinamidomethyl)piperidine-i -carboxylate
  • Amine AM13 2-((4-(4-Cyclopropylpiperazin-1-yl)piperidin-4-yl)methyl)isoindolin-1-one
  • Step-1 2-((1-Benzyl-4-(4-cyclopropylpiperazin-1-yl)piperidin-4- yl)methyl)isoindolin-1 -one
  • Step-2 2-((4-(4-Cyclopropylpiperazin-1-yl)piperidin-4-yl)methyl)isoindolin- 1-one (AM13)
  • Step 2 1-(Pyridin-4-yl)piperazine tert-Butyl 4-(pyridin-4-yl)piperazine-1-carboxylate was generated using standard de-Boc conditions (see above: 13 equiv. TFA in dichlorormethane) which was made TFA free upon work-up by stirring with basic amberlyst resin in methanol.
  • Step 4 (1-Benzyl-4-(4-(pyridin-4-yl)piperazin-1-yl)piperidin-4- yl)methanamine
  • Step 5 N-((1 -Benzyl-4-(4-(pyridin-4-yl)piperazin-1 -yl)piperidin-4- yl)methyl)acetamide (AM14) Triethylamine (2.5 equiv.) followed by acetyl chloride (1.2 equiv.) were added under cooled conditions to a solution of (1-benzyl-4-(4-(pyridin-4-yl)piperazin-1- yl)piperidin-4-yl)methanamine (4.67 mmol, 1 equiv.) in dichloromethane. The resulting solution was warmed to room temperature and stirred for 3 h. The mixture was diluted with dichloromethane and given water and brine washes respectively. The organic layer was dried over sodium sulphate, filtered and the solvent removed. The crude product was purified by column chromatography (silica). Yield: 52%
  • step-1 To a methanolic solution (20 ml) of N-benzyl piperidone (52.9 mmol) was added water (1.2 ml), N-methylpiperazine (1 eqv), acetic acid (1 eqv) and potassium cyanide (1.1 eqv). The resulting reaction mixture was allowed to stir at 25 0 C for 1 hr by which time solid was separated. It was then treated with 35% ammonium hydroxide (300 ml) and ice (100 g). Solid was filtered, washed several times with water and dried. Yield : 45%
  • Triethylamine (4.5 eq.) and the corresponding acid chloride (1.1 eq.) were added to a solution, cooled to 0 0 C, of the Boc-protected amine (1 eq.) in MC (5 ml/mmol) and the mixture was stirred at this temperature for 30 min. The reaction solution was then warmed to 25 0 C and stirred at this temperature for 1 h (TLC control). After reaction of the amine was complete, hydrolysis was carried out with ice, the mixture was diluted further with MC and the organic phase was washed with water and sat. NaCI solution. The mixture was then dried over Na 2 SO 4 and filtered and the solvent was removed in vacuo. The crude product was purified in a parallel purification system from Biotage.
  • Example 1 N-((1-(2-(2-(4-Methoxy-N,2,6- trimethylphenylsulfonamido)ethoxy)acetyl)-4-(4-methylpiperazin-1- yl)piperidin-4-yl)methyl)isonicotinamide
  • Stage 1 A mixture of N-Boc-piperidone (10.0 g, 50.2 mmol), 1-methylpiperazine (5.57 ml, 50.2 mmol), water (1.18 ml, 65.2 mmol) and acetic acid (3.18 ml, 55.2 mmol) in methanol (20 ml) was stirred at RT under a nitrogen atmosphere. KCN (3.44 g, 52.8 mmol) was added and the reaction mixture was stirred at RT. After 30 min, a solid precipitated out. Aqueous NH 4 OH solution (35 %, 300 ml) and ice (100 g) were added to the reaction mixture. The solid was filtered off, dried and employed further without further purification. Stage 2.
  • Stage 3 Triethylamine (4.2 ml, 29.7 mmol) and isonicotinoyl chloride hydrochloride (1.20 g, 6.74 mmol) were added to a solution of the crude product from stage 2. (max. 9.89 mmol) in MC (125 ml) at RT. The reaction mixture was stirred at RT for 3 h and then concentrated to dryness. The crude product was purified by column chromatography (silica gel, MC, 7 M NH 3 in methanol, 95 : 5) Stage 4. HCI (4 M in dioxane, 2.35 ml, 9.4 mmol) was added to a solution of the product from stage 3. (490 mg, 1.17 mmol) in dioxane (10 ml) and the mixture was stirred at RT for 3 h. The solvent was removed and the crude product was employed further without further purification.
  • N-((4-(4-(pyridin-4-yl)piperazin-1-yl)piperidin-4-yl)methyl)acetamide AM2 was re- dissolved in dichloromethane and added to a solution containing 2-(2-(N- cyclopropyl-4-methoxy-2,6-dimethylphenylsulfonamido)ethoxy)acetic acid AC7 (0.8 equiv.), EDCI (1.5 equiv.), HOBT (1 equiv.) and DIPEA (4 equiv.) in dichloromethane at O 0 C. The reaction mixture was warmed to room temperature and stirred for 16 h. The mixture was diluted with dichloromethane and was given aq.
  • HPLC Waters Alliance 2795 with PDA Waters 2998; MS: Micromass Quattro MicroTM API ; Column: Waters Atlantis® T3 , 3 ⁇ m, 100 A , 2.1 x 30 mm; temp.: 40 °C, Eluent A: water + 0.1% formic acid; Eluent B: acetonitrile + 0.1% formic acid; Gradient: 0% B to 100% B in 8.8 min, 100% B for 0.4 min, 100% B to 0% B in 0.01 min, 0% B for 0.8 min; Flow: 1.0 mL/min; lonisation: ES+, 25 V; Make up: 100 ⁇ L/min 70% Methanol + 0.2% formic acid; UV: 200 - 400 nm
  • Example Compounds (2) to (41) and (49) to (54) prepared by means of the parallel syntheses were analyzed, inter alia, with the aid of their molecular weight.
  • the particular method used for the synthesis and the molecular weights measured by means of ESI-MS are summarized in the following table.
  • the agonistic or antagonistic action of substances can be determined on the bradykinin 1 receptor (B1 R) of humans and rats by means of a cell-based flourescent calcium-mobilization assay.
  • B1 R bradykinin 1 receptor
  • agonist-induced increase of intracellular free Ca 2+ is quantified by means of a Ca 2+ -sensitive dye (Fluo-4 type, Molecular Probes Europe BV, Leiden, Netherlands), in a Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, USA) and/or the Novostar (BMG Labtech GmbH, Offenburg, Germany).
  • CHO K1 cells Chinese hamster ovary cells (CHO K1 cells), which are stably transfected with the human B1 R gene (hB1 R cells) or with the B1 R gene of rats (rB1 R cells), are used.
  • hB1 R cells human B1 R gene
  • rB1 R cells B1 R gene of rats
  • the cells are incubated overnight in a humidified atmosphere at 37°C and 5% CO 2 in culture medium (hB1R cells: Nutrient Mixture Ham's F12, Gibco Invitrogen GmbH, Düsseldorf, Germany or DMEM, Sigma-Aldrich, Tauf Wegn, Germany; rB1 R cells: D-MEM/F12, Gibco Invitrogen GmbH, Düsseldorf, Germany) with 10 vol.% FBS (foetal bovine serum, Gibco Invitrogen GmbH, Düsseldorf, Germany).
  • Method A The medium of the cells is removed and cell plates are incubated with loading solution, which contains 2.13 ⁇ M Fluo-4-AM, 2.5 mM probenecid (Sigma-Aldrich, Taufkirchen, Germany), and 10 mM HEPES (Sigma-Aldrich, Taufmün, Germany) in HBSS buffer (Hank's buffered saline solution, Gibco Invitrogen GmbH, Düsseldorf, Germany) for 60 minutes at 37°C.
  • loading solution contains 2.13 ⁇ M Fluo-4-AM, 2.5 mM probenecid (Sigma-Aldrich, Taufmün, Germany), and 10 mM HEPES (Sigma-Aldrich, Taufmün, Germany) in HBSS buffer (Hank's buffered saline solution, Gibco Invitrogen GmbH, Düsseldorf, Germany) for 60 minutes at 37°C.
  • HBSS buffer supplemented 0.1% BSA (bovine serum albumin; Sigma-Aldrich, Taufkirchen, Germany), 5.6 mM glucose and 0.05% gelatine (Merck KGaA 1 Darmstadt, Germany) is added.
  • BSA bovine serum albumin
  • gelatine Merck KGaA 1 Darmstadt, Germany
  • Method B The plates are washed with buffer A (15 mM HEPES, 80 mM NaCI, 5 mM KCI, 1.2 mM CaCI 2 , 0.7 mM MgSO 4 , 2 mg/ml glucose, 2.5 mM probenecid) and subsequently loaded with buffer A containing 2.4 ⁇ M Fluo-4-AM and 0.025% pluronic F127 (Sigma-Aldrich, Taufkirchen, Germany) for 60 minutes at 37°C. Cell plates are washed twice with buffer A. Then, buffer A supplemented with 0.05% BSA and 0.05% gelatine is added and cell plates are incubated in the dark at room temperature for at least 20 minutes before measurement in the FLIPR or Novostar is started.
  • buffer A 15 mM HEPES, 80 mM NaCI, 5 mM KCI, 1.2 mM CaCI 2 , 0.7 mM MgSO 4 , 2 mg/ml glucose, 2.5 mM probenecid
  • buffer A containing
  • the agonistic or antagonistic action of the compounds according to the invention on the bradykinin 1 receptor (B1 R) of the human and rat species was determined as described above.
  • Antagonists lead to a suppression of the Ca 2 increase. % inhibition compared with the maximum achievable inhibition was calculated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention porte sur des dérivés de sulfonamide substitués, sur des procédés pour leur préparation, sur des médicaments contenant ces composés et sur l'utilisation de dérivés de sulfonamide substitués pour la préparation de médicaments.
EP09717566A 2008-03-05 2009-03-04 Dérivés de sulfonamide substitués Withdrawn EP2254867A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09717566A EP2254867A1 (fr) 2008-03-05 2009-03-04 Dérivés de sulfonamide substitués

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08004073 2008-03-05
EP09717566A EP2254867A1 (fr) 2008-03-05 2009-03-04 Dérivés de sulfonamide substitués
PCT/EP2009/001520 WO2009109364A1 (fr) 2008-03-05 2009-03-04 Dérivés de sulfonamide substitués

Publications (1)

Publication Number Publication Date
EP2254867A1 true EP2254867A1 (fr) 2010-12-01

Family

ID=39672037

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09717566A Withdrawn EP2254867A1 (fr) 2008-03-05 2009-03-04 Dérivés de sulfonamide substitués

Country Status (9)

Country Link
US (1) US8541573B2 (fr)
EP (1) EP2254867A1 (fr)
JP (1) JP2011514344A (fr)
AR (1) AR070856A1 (fr)
CA (1) CA2717604A1 (fr)
CL (1) CL2009000519A1 (fr)
PE (1) PE20091807A1 (fr)
TW (1) TW200940528A (fr)
WO (1) WO2009109364A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383267A1 (fr) * 2006-09-29 2011-11-02 Grünenthal GmbH Dérivés de sulfonamide substitués
EP2262792A1 (fr) * 2008-04-08 2010-12-22 Grünenthal GmbH Dérivés de sulfonamide substitués

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338334B8 (en) * 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
US7425631B2 (en) * 2003-04-10 2008-09-16 Amgen Inc. Compounds and methods of use
JP2006522835A (ja) * 2003-04-10 2006-10-05 アムジェン インコーポレイテッド 環状アミン誘導体およびブラジキニンによって媒介される炎症関連障害の処置におけるそれらの使用
WO2007101007A2 (fr) 2006-02-23 2007-09-07 Neurogen Corporation Heterocycles sulfonyl aryliques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009109364A1 *

Also Published As

Publication number Publication date
TW200940528A (en) 2009-10-01
CL2009000519A1 (es) 2010-03-05
WO2009109364A1 (fr) 2009-09-11
JP2011514344A (ja) 2011-05-06
AR070856A1 (es) 2010-05-12
PE20091807A1 (es) 2009-11-21
CA2717604A1 (fr) 2009-09-11
US20090298812A1 (en) 2009-12-03
US8541573B2 (en) 2013-09-24

Similar Documents

Publication Publication Date Title
US8278319B2 (en) Substituted spiroamine compounds
JP5406722B2 (ja) ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体
EP2150530B1 (fr) Dérivés de sulfonamide substitués
JP2012519196A (ja) スルホニル化されたテトラヒドロアゾロピラジンおよびその医薬としての使用
US8119805B2 (en) Substituted disulfonamide compounds
EP2440542A1 (fr) Benzimidazoles, benzothiazoles et benzoxazoles substitués
EP2257527A1 (fr) Derives de sulfonamide substitues
JP2011509961A (ja) 置換スルホンアミド誘導体
US20080306084A1 (en) Substituted Amide Compounds
MXPA06003264A (es) Derivados de piridina y uso de los mismos como antagonistas de la urotensina ii.
US8318769B2 (en) Substituted sulfonamide compounds
WO2009109364A1 (fr) Dérivés de sulfonamide substitués
JP2012516860A (ja) ブラジキニンレセプター１モジュレータとしての置換されたインドール化合物
US8124624B2 (en) Substituted sulfonamide compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

17Q First examination report despatched

Effective date: 20110310

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140603